Palisade Bio Earnings Call Transcripts
Fiscal Year 2026
-
A novel oral PDE4 inhibitor prodrug for IBD demonstrated strong safety and efficacy in early trials, with phase II studies in ulcerative colitis and Crohn's disease set to begin, backed by robust funding and a top-tier clinical team. The drug's targeted delivery and tolerability differentiate it from competitors.
-
A novel oral PDE4 inhibitor prodrug for IBD showed strong early efficacy and safety in UC and Crohn's, with 100% response in a UC phase Ib and robust PK/PD in Crohn's. Phase II trials are set for 2024, supported by $135M in cash and a precision medicine approach.
-
Phase I-B data for PALI-2108 in fibrostenotic Crohn's disease showed strong safety, robust PK/PD, and early clinical activity, with 40% endoscopic response/remission in a refractory population. Once-daily oral dosing and dual anti-inflammatory/anti-fibrotic action support further development in broader Crohn's cohorts.
-
PALI-2108, a locally activated PDE4 inhibitor prodrug, is advancing in IBD with strong early efficacy and safety data, a dual anti-inflammatory/anti-fibrotic mechanism, and a robust financial runway. Key clinical milestones are set for 2024–2028, with strategic flexibility in Crohn's indications.
-
The company has restructured around a novel, gut-restricted PDE4 inhibitor with promising early clinical results in UC and FSCD. With strong financial backing and a clear development timeline, it is positioned for expansion into broader GI and potential non-GI indications.
Fiscal Year 2025
-
Upcoming milestones include early 2025 data from a Phase 1b Crohn's study and a definitive Phase II UC trial, both supported by strong fundraising. The lead PDE4 inhibitor shows rapid, potent efficacy with a favorable safety profile, targeting high unmet needs in IBD.
-
PALI-2108, a novel oral PDE4 inhibitor prodrug, shows strong safety and targeted delivery for ulcerative colitis, with promising Phase I results and potential application in Crohn's disease. The IBD market is lucrative, and further updates on development are anticipated.
Fiscal Year 2024
-
The event highlighted a novel PDE4 inhibitor for ulcerative colitis, with a precision medicine approach and strong preclinical data. The company is preparing for phase I trials, targeting a large market, and has received positive feedback from pharma partners.
-
The session highlighted a novel PDE4 inhibitor for ulcerative colitis, featuring a pro-drug formulation designed to improve efficacy and tolerability. Human trials are set to begin soon, with a precision medicine approach and strong management investment backing the program.